CN113747943A - 喹唑啉酮化合物 - Google Patents

喹唑啉酮化合物 Download PDF

Info

Publication number
CN113747943A
CN113747943A CN202080030788.4A CN202080030788A CN113747943A CN 113747943 A CN113747943 A CN 113747943A CN 202080030788 A CN202080030788 A CN 202080030788A CN 113747943 A CN113747943 A CN 113747943A
Authority
CN
China
Prior art keywords
compound
hydrogen
radical
halogen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030788.4A
Other languages
English (en)
Chinese (zh)
Inventor
鹿炳伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celepate Corp
Original Assignee
Celepate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celepate Corp filed Critical Celepate Corp
Publication of CN113747943A publication Critical patent/CN113747943A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080030788.4A 2019-02-27 2020-02-26 喹唑啉酮化合物 Pending CN113747943A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811471P 2019-02-27 2019-02-27
US62/811,471 2019-02-27
PCT/US2020/019942 WO2020176652A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Publications (1)

Publication Number Publication Date
CN113747943A true CN113747943A (zh) 2021-12-03

Family

ID=72238692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030788.4A Pending CN113747943A (zh) 2019-02-27 2020-02-26 喹唑啉酮化合物

Country Status (9)

Country Link
US (1) US12454514B2 (https=)
EP (1) EP3930837A4 (https=)
JP (1) JP7597722B2 (https=)
KR (1) KR20210139279A (https=)
CN (1) CN113747943A (https=)
AU (1) AU2020228374A1 (https=)
CA (1) CA3131294A1 (https=)
IL (1) IL285805A (https=)
WO (1) WO2020176652A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
CN111372921A (zh) * 2017-09-13 2020-07-03 赛勒佩特公司 新型小分子化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
WO2013025508A1 (en) * 2011-08-12 2013-02-21 Southern Research Institute Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20190307749A1 (en) * 2018-04-10 2019-10-10 Texas Tech University System Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
CN111372921A (zh) * 2017-09-13 2020-07-03 赛勒佩特公司 新型小分子化合物

Also Published As

Publication number Publication date
US20220162172A1 (en) 2022-05-26
US12454514B2 (en) 2025-10-28
AU2020228374A1 (en) 2021-09-23
WO2020176652A1 (en) 2020-09-03
EP3930837A4 (en) 2022-10-05
KR20210139279A (ko) 2021-11-22
IL285805A (en) 2021-10-31
JP2022523383A (ja) 2022-04-22
JP7597722B2 (ja) 2024-12-10
CA3131294A1 (en) 2020-09-03
EP3930837A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
TWI891621B (zh) 一種噠嗪類衍生物抑制劑、其製備方法和應用
TWI896726B (zh) 一種ｅｇｆｒ抑制劑及其製備方法和應用
WO2022007841A1 (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
EP4570794A1 (en) Heterocyclic compound for inhibiting and/or inducing degradation of kras protein
WO2022105908A1 (zh) Egfr抑制剂及其制备方法与在药学上的应用
TWI732810B (zh) 苯并哌啶類衍生物、其製備方法及其在醫藥上的應用
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
JP6506291B2 (ja) 短縮型大腸腺腫性ポリポーシス（ａｐｃ）タンパク質を標的にする治療剤
TW202019925A (zh) 吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2020093905A1 (zh) 并环化合物、其制备方法及用途
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
TW202317563A (zh) 一種聯苯類衍生物抑制劑的晶型及其製備方法
TW202019886A (zh) 雜芳基類衍生物、其製備方法及其在醫藥上的應用
JP2020512002A (ja) 幹細胞を分化し、癌を処置するための作用薬
TW202321241A (zh) 嘧啶或吡啶衍生物及其製備方法和在藥學上的應用
CN113747943A (zh) 喹唑啉酮化合物
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
RU2712140C2 (ru) Композиции для лечения фиброза и связанных с фиброзом состояний
CN111372921B (zh) 小分子化合物
CN107501279A (zh) 呋喃并喹啉二酮类化合物及其医药用途
KR101693326B1 (ko) 3,4-디히드로퀴나졸린 유도체 및 그를 포함하는 복합제
WO2012045734A1 (en) Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
CN116670126A (zh) 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
CN114716440A (zh) 吡咯并三嗪衍生物及其制备方法和应用
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination